Ashish Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashish Kumar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Rahul Shukla
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-Raebareli)
2 shared publications Ajit Singh
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-R)-Raebareli, Lucknow, Uttar Pradesh 226002, India
1 shared publication- Awanish Mishra
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) - Guwahati, Changsari, Kamrup, Assam 781101, India
1 shared publication Biplab Sikdar
Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research-Raebareli (NIPER-R), Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow-226002, U.P., India
1 shared publicationGagandeep Maan
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research-Raebareli (NIPER-R), Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow-226002, U.P., India
1 shared publicationRahul K. Verma
Institute of Nano Science and Technology (INST), Phase X, Sector 64, Mohali, Punjab 12 160062, India
1 shared publication
Latest Publications
- 9 June 2020
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 20 (13) , 1169-1194
Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Background: Flavonoids, a group of natural dietary polyphenols, are known for their beneficial effects on human health. By virtue of their various pharmacological effects, like anti-oxidative, antiinflammatory, anti-carcinogenic and neuroprotective effects, flavonoids have now become an important component of herbal supplements, pharmaceuticals, medicinals and cosmetics. There has been enormous literature supporting neuroprotective effect of flavonoids. Recently their efficacy in various neurodegenerative diseases, like Alzheimer’s disease and Parkinson diseases, has received particular attention.Objective: The mechanism of flavanoids neuroprotection might include antioxidant, antiapoptotic, antineuroinflammatory and modulation of various cellular and intracellular targets. In in-vivo systems, before reaching to brain, they have to cross barriers like extensive first pass metabolism, intestinal barrier and ultimately blood brain barrier. Different flavonoids have varied pharmacokinetic characteristics, which affect their pharmacodynamic profile. Therefore, brain accessibility of flavonoids is still debatable.Methods: This review emphasized on current trends of research and development on flavonoids, especially in neurodegenerative diseases, possible challenges and strategies to encounter using novel drug delivery system.Results: Various flavonoids have elicited their therapeutic potential against neurodegenerative diseases, however by using nanotechnology and novel drug delivery systems, the bioavailability of favonoids could be enhanced.Conclusion: This study bridges a significant opinion on medicinal chemistry, ethanopharmacology and new drug delivery research regarding use of flavonoids in management of neurodegeneration.
- 9 June 2020
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 20 (13) , 1169-1194
Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Background: Flavonoids, a group of natural dietary polyphenols, are known for their beneficial effects on human health. By virtue of their various pharmacological effects, like anti-oxidative, antiinflammatory, anti-carcinogenic and neuroprotective effects, flavonoids have now become an important component of herbal supplements, pharmaceuticals, medicinals and cosmetics. There has been enormous literature supporting neuroprotective effect of flavonoids. Recently their efficacy in various neurodegenerative diseases, like Alzheimer’s disease and Parkinson diseases, has received particular attention.Objective: The mechanism of flavanoids neuroprotection might include antioxidant, antiapoptotic, antineuroinflammatory and modulation of various cellular and intracellular targets. In in-vivo systems, before reaching to brain, they have to cross barriers like extensive first pass metabolism, intestinal barrier and ultimately blood brain barrier. Different flavonoids have varied pharmacokinetic characteristics, which affect their pharmacodynamic profile. Therefore, brain accessibility of flavonoids is still debatable.Methods: This review emphasized on current trends of research and development on flavonoids, especially in neurodegenerative diseases, possible challenges and strategies to encounter using novel drug delivery system.Results: Various flavonoids have elicited their therapeutic potential against neurodegenerative diseases, however by using nanotechnology and novel drug delivery systems, the bioavailability of favonoids could be enhanced.Conclusion: This study bridges a significant opinion on medicinal chemistry, ethanopharmacology and new drug delivery research regarding use of flavonoids in management of neurodegeneration.
- 1 April 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 149, 1198-1206
Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity
- 1 April 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 149, 1198-1206
Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity